ArticleClinicoEconomics and outcomes research : CEOR2026
Clinical and Economic Burden Following Percutaneous Coronary Intervention for STEMI: A US Real-World Evidence Study.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: ST-segment-elevation myocardial infarction (STEMI) affects approximately 250,000 people in the U.S. annually, causing substantial morbidity and mortality. One-year outcomes following percutaneous coronary intervention (PCI) for STEMI vary across studies. Aim: To assess clinical and economic outcomes following PCI among patients with STEMI. Methods: This study analyzed adult patients with STEMI undergoing PCI between 2016 and 2021, using Premier Healthcare Database and additional mortality and claims data. Clinical outcomes, healthcare resource use, and costs following first PCI discharge (index visit) were assessed for at least 1 year, with outcomes at 3-year follow-up assessed among a subset of patients. Multivariable regression (Cox, logistic or generalized linear) was used to identify risk factors for key outcomes. Results: A total of 180,691 patients underwent PCI for STEMI in 633 US hospitals during the study period. The median age was 62 years, most were male (71%), non-Hispanic White (62.7%), and had Medicare as the primary payor (42.9%). At index visit, 13.8% had ventricular tachycardia, 8.8% had ventricular fibrillation, with a median cost of $17,582, and a mortality rate of 5.5%. Within 1 year, there were 1,966 (1.1%) additional deaths, 17.4% were readmitted, 13.4% developed heart failure (HF), 2.5% were hospitalized primarily for HF (HHF), 3.9% had atrial fibrillation, and 1% experienced recurrent STEMI. The median total study cost by 1 year was $21,010. A Charlson Comorbidity Index (CCI) score of ≥4 (vs <4) at index visit was most strongly associated with higher risk of death at 1 year: hazard ratio: 4.1, (95% CI: 3.66 to 4.49), higher odds of readmissions (OR: 2.6, 95% CI: 2.50 to 2.70), HHF (OR: 4.1 (95% CI: 3.83 to 4.42)), and 74% higher costs (p<0.05). Similar associations were observed at 3-year follow-up (n=59,714). Conclusion: This study identified risk factors associated with one-year negative clinical outcomes and increased cost following PCI for the treatment of STEMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.